These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 20130526)

  • 1. p35, the non-cyclin activator of Cdk5, protects podocytes against apoptosis in vitro and in vivo.
    Brinkkoetter PT; Wu JS; Ohse T; Krofft RD; Schermer B; Benzing T; Pippin JW; Shankland SJ
    Kidney Int; 2010 Apr; 77(8):690-9. PubMed ID: 20130526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High glucose increases Cdk5 activity in podocytes via transforming growth factor-β1 signaling pathway.
    Zhang Y; Li H; Hao J; Zhou Y; Liu W
    Exp Cell Res; 2014 Aug; 326(2):219-29. PubMed ID: 24768698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Both cyclin I and p35 are required for maximal survival benefit of cyclin-dependent kinase 5 in kidney podocytes.
    Taniguchi Y; Pippin JW; Hagmann H; Krofft RD; Chang AM; Zhang J; Terada Y; Brinkkoetter P; Shankland SJ
    Am J Physiol Renal Physiol; 2012 May; 302(9):F1161-71. PubMed ID: 22262481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knockdown of Expression of Cdk5 or p35 (a Cdk5 Activator) Results in Podocyte Apoptosis.
    Zheng YL; Zhang X; Fu HX; Guo M; Shukla V; Amin ND; E J; Bao L; Luo HY; Li B; Lu XH; Gao YC
    PLoS One; 2016; 11(8):e0160252. PubMed ID: 27479491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo.
    Logar CM; Brinkkoetter PT; Krofft RD; Pippin JW; Shankland SJ
    Kidney Int; 2007 Aug; 72(4):489-98. PubMed ID: 17554257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin-dependent kinase 5 is a regulator of podocyte differentiation, proliferation, and morphology.
    Griffin SV; Hiromura K; Pippin J; Petermann AT; Blonski MJ; Krofft R; Takahashi S; Kulkarni AB; Shankland SJ
    Am J Pathol; 2004 Oct; 165(4):1175-85. PubMed ID: 15466384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cyclin-dependent kinase inhibitor p21 is required for TGF-beta1-induced podocyte apoptosis.
    Wada T; Pippin JW; Terada Y; Shankland SJ
    Kidney Int; 2005 Oct; 68(4):1618-29. PubMed ID: 16164639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Podocyte expression of the CDK-inhibitor p57 during development and disease.
    Hiromura K; Haseley LA; Zhang P; Monkawa T; Durvasula R; Petermann AT; Alpers CE; Mundel P; Shankland SJ
    Kidney Int; 2001 Dec; 60(6):2235-46. PubMed ID: 11737597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of d-type cyclins in podocytes in vitro and in vivo.
    Petermann A; Hiromura K; Pippin J; Blonski M; Couser WG; Kopp J; Mundel P; Shankland SJ
    Am J Pathol; 2004 Apr; 164(4):1417-24. PubMed ID: 15039229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Atypical Cyclin-Dependent Kinase 5 (Cdk5) Guards Podocytes from Apoptosis in Glomerular Disease While Being Dispensable for Podocyte Development.
    Mangold N; Pippin J; Unnersjoe-Jess D; Koehler S; Shankland S; Brähler S; Schermer B; Benzing T; Brinkkoetter PT; Hagmann H
    Cells; 2021 Sep; 10(9):. PubMed ID: 34572114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin I activates Cdk5 and regulates expression of Bcl-2 and Bcl-XL in postmitotic mouse cells.
    Brinkkoetter PT; Olivier P; Wu JS; Henderson S; Krofft RD; Pippin JW; Hockenbery D; Roberts JM; Shankland SJ
    J Clin Invest; 2009 Oct; 119(10):3089-101. PubMed ID: 19729834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosuvastatin protects against podocyte apoptosis in vitro.
    Cormack-Aboud FC; Brinkkoetter PT; Pippin JW; Shankland SJ; Durvasula RV
    Nephrol Dial Transplant; 2009 Feb; 24(2):404-12. PubMed ID: 18820279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nestin protects mouse podocytes against high glucose-induced apoptosis by a Cdk5-dependent mechanism.
    Liu W; Zhang Y; Hao J; Liu S; Liu Q; Zhao S; Shi Y; Duan H
    J Cell Biochem; 2012 Oct; 113(10):3186-96. PubMed ID: 22614921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPAR-gamma agonist protects podocytes from injury.
    Kanjanabuch T; Ma LJ; Chen J; Pozzi A; Guan Y; Mundel P; Fogo AB
    Kidney Int; 2007 Jun; 71(12):1232-9. PubMed ID: 17457378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin I and p35 determine the subcellular distribution of Cdk5.
    Hagmann H; Taniguchi Y; Pippin JW; Kauerz HM; Benzing T; Shankland SJ; Brinkkoetter PT
    Am J Physiol Cell Physiol; 2015 Feb; 308(4):C339-47. PubMed ID: 25500740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin I protects podocytes from apoptosis.
    Griffin SV; Olivier JP; Pippin JW; Roberts JM; Shankland SJ
    J Biol Chem; 2006 Sep; 281(38):28048-57. PubMed ID: 16847066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin I-Cdk5 governs survival in post-mitotic cells.
    Brinkkoetter PT; Pippin JW; Shankland SJ
    Cell Cycle; 2010 May; 9(9):1729-31. PubMed ID: 20404535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dexamethasone prevents podocyte apoptosis induced by puromycin aminonucleoside: role of p53 and Bcl-2-related family proteins.
    Wada T; Pippin JW; Marshall CB; Griffin SV; Shankland SJ
    J Am Soc Nephrol; 2005 Sep; 16(9):2615-25. PubMed ID: 15987750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of p53 deSUMOylation exacerbates puromycin aminonucleoside-induced apoptosis in podocytes.
    Wang L; Zhu J; Fang M; Zhang T; Xie H; Wang N; Shen N; Guo H; Fu B; Lin H
    Int J Mol Sci; 2014 Nov; 15(11):21314-30. PubMed ID: 25411797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell cycle regulatory proteins in podocyte health and disease.
    Marshall CB; Shankland SJ
    Nephron Exp Nephrol; 2007; 106(2):e51-9. PubMed ID: 17570940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.